Predictors of Days Unable to Work Among Genotype 1 Treatment-NaiVE Chronic Hepatitis C Patients: Post-Hoc Analyses of Data From Phase 3 Advance and Illuminate Studies

被引：0
|
作者：
Hernandez, Ning C.
Vera-Llonch, Montserrat
Aggarwal, Jyoti
Donepudi, Mrudula
Younossi, Zobair M.
Goss, Thomas F.
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S955 / S955
页数：1
相关论文
共 50 条
  • [41] Treatment of chronic Hepatitis C genotype 1 (G1) infection with Boceprevir (Victrelis®) in the German real-life setting: high early virologic response rates in treatment-naive patients from the NOVUS observational study
    Buggisch, Peter
    Loehr, Hanns F.
    Teuber, Gerlinde
    Steffens, Hermann
    Kraus, Michael R. R.
    John, Christine
    Geyer, Peter R.
    Weber, Bernd
    Witthoeft, Thomas
    Herrmann, Andreas
    Hoesl, Mark
    Naumann, Uwe
    Dahhan, Tarek
    Hartmann, Dagmar
    Dreher, Bernd
    Bilzer, Manfred
    HEPATOLOGY, 2013, 58 : 1132A - 1133A
  • [42] A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
    Tatum, H.
    Thuluvath, P.
    Lawitz, E.
    Martorell, C. T.
    Demicco, M.
    Cohen, S.
    Rustgi, V.
    Ravendhran, N.
    Ghalib, R.
    Hanson, J.
    Zamparo, J.
    Yang, R.
    Hughes, E.
    Cooney, E.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S460 - S460
  • [43] DO PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1, TREATED BY NEW AGENTS IN PHASE 2/3 STUDIES DIFFER FROM THOSE RECEIVING STANDARD OF CARE?
    Beinhardt, Sandra
    Staettermayer, Albert
    Rutter, Karoline
    Scherzer, Thomas-Matthias
    Hofer, Harold
    Steindl-Munda, Petra E.
    Fer-enci, Peter
    HEPATOLOGY, 2009, 50 (04) : 720A - 720A
  • [44] ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR-4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016)
    Bronowicki, J. -P.
    Ratziu, V.
    Gadano, A.
    Thuluvath, P. J.
    Bessone, F.
    Martorell, C. T.
    Pol, S.
    Terg, R.
    Younes, Z.
    He, B.
    Eley, T.
    Cohen, D.
    Mendez, P.
    Hughes, E. A.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S571 - S572
  • [45] Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (vol 386, pg 1537, 2015)
    Roth, D.
    Nelson, D. R.
    Bruchfeld, A.
    LANCET, 2015, 386 (10006): : 1824 - 1824
  • [46] Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
    Mizokami, Masashi
    Yokosuka, Osamu
    Takehara, Tetsuo
    Sakamoto, Naoya
    Korenaga, Masaaki
    Mochizuki, Hitoshi
    Nakane, Kunio
    Enomoto, Hirayuki
    Ikeda, Fusao
    Yanase, Mikio
    Toyoda, Hidenori
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Betular, Juan
    Gao, Bing
    Ishizaki, Akinobu
    Omote, Masa
    Mo, Hongmei
    Garrison, Kim
    Pang, Phillip S.
    Knox, Steven J.
    Symonds, William T.
    McHutchison, John G.
    Izumi, Namiki
    Omata, Masao
    LANCET INFECTIOUS DISEASES, 2015, 15 (06): : 645 - 653
  • [47] HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C
    Kwo, P.
    Lawitz, E.
    McCone, J.
    Schiff, E.
    Vierling, J.
    Pound, D.
    Davis, M.
    Galati, J.
    Gordon, S.
    Ravendhran, N.
    Rossaro, L.
    Anderson, F.
    Jacobson, I.
    Rubin, R.
    Koury, K.
    Brass, C.
    Chaudhri, E.
    Albrecht, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S4 - S4
  • [48] Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study
    Gane, Edward J.
    Kocinsky, Hetal
    Schwabe, Christian
    Mader, Michael
    Suri, Vithika
    Donohue, Mary K.
    Huang, Mingjun
    Hui, James
    Yang, Joanna
    Apelian, David
    HEPATOLOGY, 2014, 60 (06) : 1281A - 1282A
  • [49] EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND COMPENSATED CIRRHOSIS: EXPEDITION-8 COMPLETE RESULTS
    Brown, Robert S., Jr.
    Buti, Maria
    Rodrigues, Lino
    Chulanov, Vladimir
    Chuang, Wan Long
    Aguilar, Humberto
    Horvath, Gabor
    Zuckerman, Elimelech
    Rosado-Carrion, Barbara
    Rodriguez-Perez, Federico
    Urbanek, Petr
    Abergel, Armand
    Cohen, Eric
    Lovell, Sandra Sinisi
    Schnell, Gretja
    Lin, Chih-Wei
    Zha, Jiuhong
    Wang, Stanley
    Trinh, Roger
    Mensa, Federico J.
    Burroughs, Margaret
    Felizarta, Franco
    HEPATOLOGY, 2019, 70 (06) : 1493A - 1494A
  • [50] EARLY VIRAL RESPONSE (EVR) RATES IN TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION TREATED WITH MK-7009, A NOVEL NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
    Manns, Michael P.
    Gane, Edward J.
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht D.
    Yeh, Chau-Ting
    Marcellin, Patrick
    Wiedmann, Richard T.
    Hwang, Peggy
    Barnard, Richard J.
    Quirk, Erin
    Kartsonis, Nicholas A.
    Lee, Andrew W.
    HEPATOLOGY, 2009, 50 (04) : 332A - 333A
12345